Skip to main navigation Skip to search Skip to main content

An Open-Label Phase 2 Study to Evaluate the Safety, Tolerability, and Effect on Albuminuria of MZE829 in Adults with Proteinuric Chronic Kidney Disease and the APOL1 High Risk Genotype

Project: Research

Project Details

StatusActive
Effective start/end date04/6/26 → 12/1/26

Funding

  • Maze Therapeutics Incorporated: $6,604.00